Literature DB >> 16944253

In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae.

Ryusaburo Furuya1, Hiroshi Nakayama, Akiko Kanayama, Takeshi Saika, Takako Iyoda, Mitsuhiro Tatewaki, Kaoru Matsuzaki, Intetsu Kobayashi, Masatoshi Tanaka.   

Abstract

In Japan, Neisseria gonorrhoeae, a sexually transmitted pathogen, has recently shown significant resistance to various antimicrobial agents. In this study, a checkerboard method was utilized to investigate the in vitro activities of cefixime (CFIX), cefteram (CFTM), or amoxicillin (AMPC) in combination with azithromycin (AZM) against 25 clinical isolates of N. gonorrhoeae. Synergy, defined as a fractional inhibitory concentration (FIC) index of less than or equal to 0.50, was observed in 32% of isolates with CFIX+AZM, 12% of isolates with CFTM+AZM, and 4% of isolates with AMPC+AZM. Moreover, partial synergy, defined as an FIC index of greater than 0.50 and less than 1, was observed in 44% of isolates with CFIX+AZM, 68% of isolates with CFTM+AZM, and 52% of isolates with AMPC+AZM. In particular, as a result of the combination of CFIX and AZM, for all isolates, significant reductions were observed in the median CFIX minimum inhibitory concentration (MIC; from 0.25 to 0.008 microg/ml; P < 0.0001) and the median AZM MIC (from 0.12 to 0.03 microg/ml; P < 0.0001). However, antagonism, defined as an FIC index of greater than 1, was observed in only 4% of the isolates with both CFIX+AZM and CFTM+AZM, while it was seen in 12% of the isolates with AMPC+AZM. To our knowledge, this is the first study to demonstrate that the in vitro activity of CFIX against N. gonorrhoeae can be significantly enhanced in combination with AZM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16944253     DOI: 10.1007/s10156-006-0445-z

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  12 in total

Review 1.  Mechanisms of drug combinations: interaction and network perspectives.

Authors:  Jia Jia; Feng Zhu; Xiaohua Ma; Zhiwei Cao; Zhiwei W Cao; Yixue Li; Yixue X Li; Yu Zong Chen
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

2.  In Vitro Fractional Inhibitory Concentration (FIC) Study of Cefixime and Azithromycin Fixed Dose Combination (FDC) Against Respiratory Clinical Isolates.

Authors:  Saiprasad Vilas Patil; Anoop Laxminarayan Hajare; Manjusha Patankar; K Krishnaprasad
Journal:  J Clin Diagn Res       Date:  2015-02-01

Review 3.  Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.

Authors:  Magnus Unemo; Robert A Nicholas
Journal:  Future Microbiol       Date:  2012-12       Impact factor: 3.165

4.  In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae.

Authors:  Lindley A Barbee; Olusegun O Soge; King K Holmes; Matthew R Golden
Journal:  J Antimicrob Chemother       Date:  2014-01-26       Impact factor: 5.790

5.  A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea.

Authors:  Lindley A Barbee; Roxanne P Kerani; Julia C Dombrowski; Olusegun O Soge; Matthew R Golden
Journal:  Clin Infect Dis       Date:  2013-02-13       Impact factor: 9.079

6.  Azithromycin resistance is coevolving with reduced susceptibility to cephalosporins in Neisseria gonorrhoeae in Ontario, Canada.

Authors:  Vanessa G Allen; Christine Seah; Irene Martin; Roberto G Melano
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

Review 7.  Mechanism of action, resistance, synergism, and clinical implications of azithromycin.

Authors:  Mohsen Heidary; Ahmad Ebrahimi Samangani; Abolfazl Kargari; Aliakbar Kiani Nejad; Ilya Yashmi; Moloudsadat Motahar; Elahe Taki; Saeed Khoshnood
Journal:  J Clin Lab Anal       Date:  2022-04-21       Impact factor: 3.124

8.  Emerging azithromycin-resistance among the Neisseria gonorrhoeae strains isolated in Hungary.

Authors:  Alexandra Brunner; Eva Nemes-Nikodem; Csaba Jeney; Dora Szabo; Marta Marschalko; Sarolta Karpati; Eszter Ostorhazi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-09-20       Impact factor: 3.944

Review 9.  An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.

Authors:  Anand Kumar
Journal:  Virulence       Date:  2013-11-01       Impact factor: 5.882

10.  The prevalence and epidemiology of plasmid-mediated penicillin and tetracycline resistance among Neisseria gonorrhoeae isolates in Guangzhou, China, 2002-2012.

Authors:  Heping Zheng; Xingzhong Wu; Jinmei Huang; Xiaolin Qin; Yaohua Xue; Weiying Zeng; Yinyuan Lan; Jiangli Ou; Sanmei Tang; Mingheng Fang
Journal:  BMC Infect Dis       Date:  2015-10-09       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.